MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5503-5503 ◽  
Author(s):  
Sandro Pignata ◽  
Domenica Lorusso ◽  
Giovanni Scambia ◽  
Daniela Sambataro ◽  
Stefano Tamberi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Weekly Paclitaxel ◽  
Multicenter Phase ◽  
Platinum Resistant ◽  
Trial Testing

Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS5612-TPS5612 ◽  
Author(s):  
Robert Michael Wenham ◽  
Sachin M. Apte ◽  
Mian M. Shahzad ◽  
Jae K Lee ◽  
Denise Dorman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Weekly Paclitaxel ◽  
Platinum Resistant ◽  
Dose Dense

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5565-5565 ◽  
Author(s):  
Guenter Emons ◽  
Christian Kurzeder ◽  
Barbara Schmalfeldt ◽  
Alexander Reuss ◽  
Nikolaus de Gregorio ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Endometrial Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Study Group ◽  
Multicenter Phase ◽  
Platinum Resistant ◽  
Recurrent Endometrial Cancer
Sign in / Sign up

Export Citation Format

Share Document